Researchers have found in phase 3 ORIGIN 3 trial that investigational dual BAFF/APRIL inhibitor atacicept significantly ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

A jury Friday convicted Alphonso Payne of murdering Joshua Jalovick, a federal informant, in addition to nine other counts he ...

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is a chronic kidney disorder characterized by deposition of IgA antibodies in the glomeruli, which leads to inflammation and progressive renal ...

A new poll finds Elon Musk has lost some of his luster with Republicans since his public falling-out with President Trump.

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...